These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11461758)

  • 1. CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-alpha]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors.
    Castro A; Abasolo MI; Gil C; Segarra V; Martinez A
    Eur J Med Chem; 2001 Apr; 36(4):333-8. PubMed ID: 11461758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors.
    Martínez A; Castro A; Gil C; Miralpeix M; Segarra V; Doménech T; Beleta J; Palacios JM; Ryder H; Miró X; Bonet C; Casacuberta JM; Azorín F; Piña B; Puigdoménech P
    J Med Chem; 2000 Feb; 43(4):683-9. PubMed ID: 10691694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative molecular field analysis (CoMFA) of phthalazine derivatives as phosphodiesterase IV inhibitors.
    Chakraborti AK; Gopalakrishnan B; Sobhia ME; Malde A
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2473-9. PubMed ID: 12852946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
    Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR studies of indole derivatives as phosphodiesterase IV inhibitors.
    Chakraborti AK; Gopalakrishnan B; Sobhia ME; Malde A
    Eur J Med Chem; 2003; 38(11-12):975-82. PubMed ID: 14642329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
    Kempson J; Pitts WJ; Barbosa J; Guo J; Omotoso O; Watson A; Stebbins K; Starling GC; Dodd JH; Barrish JC; Felix R; Fischer K
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1829-33. PubMed ID: 15780616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CoMFA and CoMSIA 3D-quantitative structure-activity relationship model on benzodiazepine derivatives, inhibitors of phosphodiesterase IV.
    Ducrot P; Andrianjara CR; Wrigglesworth R
    J Comput Aided Mol Des; 2001 Sep; 15(9):767-85. PubMed ID: 11776290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and structure-activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors.
    Raboisson P; Lugnier C; Muller C; Reimund JM; Schultz D; Pinna G; Le Bec A; Basaran H; Desaubry L; Gaudiot F; Seloum M; Bourguignon JJ
    Eur J Med Chem; 2003 Feb; 38(2):199-214. PubMed ID: 12620664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.
    Bernardelli P; Lorthiois E; Vergne F; Oliveira C; Mafroud AK; Proust E; Pham N; Ducrot P; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Chevalier E; Descours A; Berlioz-Seux F; Berna P; Li M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4627-31. PubMed ID: 15324877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Ducrot P; Wrigglesworth R; Berlioz-Seux F; Coleon F; Chevalier E; Moreau F; Idrissi M; Tertre A; Descours A; Berna P; Li M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4615-21. PubMed ID: 15324875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.
    Devillers I; Pevet I; Jacobelli H; Durand C; Fasquelle V; Puaud J; Gaudillière B; Idrissi M; Moreau F; Wrigglesworth R
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3303-6. PubMed ID: 15149695
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of a potent new chemotype for the selective inhibition of PDE4.
    Skoumbourdis AP; Huang R; Southall N; Leister W; Guo V; Cho MH; Inglese J; Nirenberg M; Austin CP; Xia M; Thomas CJ
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1297-303. PubMed ID: 18243697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors.
    Barnes MJ; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Galvin FC; Gowers L; Haughan AF; Lowe C; Meissner JW; Montana JG; Morgan T; Picken CL; Watson RJ
    Bioorg Med Chem Lett; 2001 Apr; 11(8):1081-3. PubMed ID: 11327595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of (R)- and (S)-isomer of 7-methyl- or 8-alkyl-4,5,7,8-tetrahydroimidazo[2,1-i]- purin-5-one.
    Suzuki H; Nomura M; Miyamoto K; Sawanishi H; Yamamoto K
    Biol Pharm Bull; 2004 Mar; 27(3):357-60. PubMed ID: 14993802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.
    Charpiot B; Brun J; Donze I; Naef R; Stefani M; Mueller T
    Bioorg Med Chem Lett; 1998 Oct; 8(20):2891-6. PubMed ID: 9873643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.
    Ducharme Y; Friesen RW; Blouin M; Côté B; Dubé D; Ethier D; Frenette R; Laliberté F; Mancini JA; Masson P; Styhler A; Young RN; Girard Y
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1923-6. PubMed ID: 12749899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of heterocycle condensed purines.
    Suzuki H; Yamamoto M; Shimura S; Miyamoto K; Yamamoto K; Sawanishi H
    Chem Pharm Bull (Tokyo); 2002 Sep; 50(9):1163-8. PubMed ID: 12237530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
    Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
    J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors.
    Huang Y; Wu XN; Zhou Q; Wu Y; Zheng D; Li Z; Guo L; Luo HB
    J Med Chem; 2020 Dec; 63(24):15852-15863. PubMed ID: 33291877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.